CRANBURY, N.J., July 18, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,755,102 shares of common stock. As a result, the Company issued a total of 21,122,449 shares in the offering at a price of $12.25 per share.
The gross proceeds from the offering to Amicus are expected to be $258.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC acted as joint book-running managers and BofA Merrill Lynch and Cowen acted as co-lead managers for the offering.
The Company expects to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes, which may include working capital, capital expenditures, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property, the acquisition of assets or businesses that are complementary to the Company’s existing business and general and administrative expenses.
Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone number: 866-803-9204), or Goldman Sachs & Co. LLC, by mail, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile: 212-902-9316, by email: prospectus-ny@ny.email.gs.com; or by telephone: 866-471-2526.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
Forward-Looking Statements
Statements in this press release concerning Amicus’ future expectations, plans and prospects, including, without limitation, statements regarding the use of proceeds from the public offering, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results or events may differ materially from those indicated by forward-looking statements as a result of various risks, uncertainties and important factors, including those set forth in the “Risk Factors” section in the prospectus supplement relating to the offering. In addition, all forward-looking statements are subject to other risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as amended, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
FOLD—G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino, IRC Senior Director, Investor Relations spellegrino@amicusrx.com (609) 662-5044 Media: W2O Group Brian Reid breid@w2ogroup.com (212) 257-6725
